Carboplatin (JM 8), Adriamycin and Cyclophosphamide (JAC) in Advanced Ovarian Carcinoma: A Pilot Study

Autor: Conte, Pier Franco, Bruzzone, Milena, Chiara, Silvana, Rosso, Riccardo, Giaccone, Giuseppe, Carnino, Flavio, Guercio, Elso, Ragni, Nicola, Foglia, Gianni, Bentivoglio, Giorgio, Pescetto, Giuseppe, Materman, Eric, Franks, Chris
Zdroj: Tumori Journal; April 1988, Vol. 74 Issue: 2 p217-220, 4p
Abstrakt: Eleven untreated patients with advanced ovarian cancer were studied for tolerance and response to combination treatment with fixed doses of adriamycin (45 mg/m2) and cyclophosphamide (600 mg/m2) + escalating doses of carboplatin. At the first dose level of carboplatin (200 mg/m2), toxicity was acceptable. With carboplatin at 300 mg/m2, severe hematologic toxicity was observed. The dose-limiting toxicity was leukopenia. Although carboplatin was administered without any hydration, no patient experienced renal toxicity. Eight objective responses were observed in 9 clinically evaluable patients. At second look surgery, 3 complete responses and 4 partial responses were documented. Polychemotherapy with JAC (carboplatin, 200 mg/m2, adriamycin, 45 mg/m2, and cyclophosphamide, 600 mg/m2) is administrable with acceptable toxicity.
Databáze: Supplemental Index